Looking at AI in Drug Discovery begins with a fascinating episode featuring Dr David Wright, CTO and Co-Founder of Kuano. The discussion delved deep into the revolutionary role Kauno is playing in the Drug Discovery process.

Dr David Wright is the CTO and Co-Founder of ⁠Kuano⁠, a startup whose mission is to use a unique combination of simulation and AI to bring quantum detail to drug design. By starting from an exquisitely detailed picture of enzyme mechanisms they are looking to create a new generation of therapeutics, whose current projects include creating novel anti-bowel cancer drugs.

Before co-founding Kuano, Dr Wright used simulation to understand how atomic details impact drug binding at UCL. His journey to Kuano involved collaborating in large international collaborative projects (CompbioMed, CCP-SAS, CHAIN, INSPIRE) that brought together experts from the supercomputing, academic and pharmaceuticals world to advance drug design. His multidisciplinary outlook is reflected in how Kuano is bringing a new perspective to structure-based drug design.